Anti-influenza therapeutic options available to date are viral M2 ion channel inhibitors (e.g., amantadine and rimantadine) and neuraminidase (NA) inhibitors (e.g., oseltamivir, zanamivir and peramivir). This evidence concerns the gene XK and influenza.